Gut Microbiota and Immune Checkpoint Inhibitors: A Synergistic Approach in Hepatocellular Carcinoma Therapy
<p id="p2">This chapter explores the complex interplay between gut microbiota (GM), immune checkpoint inhibitors, and HCC. HCC, the most common form of primary liver cancer, often arises from chronic liver diseases influenced by the gut-liver axis. Dysbiosis of the GM—characterized by imbalanc...
Saved in:
| Main Authors: | , , , , , , |
|---|---|
| Format: | Book Chapter |
| Language: | English |
| Published: |
IntechOpen
2026
|
| Subjects: | |
| Online Access: | https://www.intechopen.com/chapters/1214765 |
| Tags: |
No Tags, Be the first to tag this record!
|
Similar Items: Gut Microbiota and Immune Checkpoint Inhibitors: A Synergistic Approach in Hepatocellular Carcinoma Therapy
- Immune Checkpoint Inhibitors for Hepatocellular Carcinoma: Recent Advances
- Statin Therapy and Gut Microbiota
- Recent Advances in Systemic Therapy for Malignant Pleural Mesothelioma: Focus on Anti-Angiogenic Inhibitors and Immune Checkpoint Inhibitors
- Systemic Therapy in Hepatocellular Carcinoma
- Neoadjuvant Immune Checkpoint Inhibitors and Antibody-Drug Conjugates in Urothelial Carcinoma: Current Evidence and Future Perspectives
- Immune and Cell Cycle Checkpoint Inhibitors for Cancer Immunotherapy